Advertisement

Topics

Breakthrough status for AZ’ lung cancer drug Imfinzi

06:40 EDT 31 Jul 2017 | PharmaTimes

US regulators have granted AstraZeneca’s Imfinzi breakthrough status for the treatment of certain patients with locally-advanced, unresectable non-small cell lung cancer (NSCLC).

Original Article: Breakthrough status for AZ’ lung cancer drug Imfinzi

NEXT ARTICLE

More From BioPortfolio on "Breakthrough status for AZ’ lung cancer drug Imfinzi"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...